Share

May 30, 2017; 88 (22) Article

Increased connectivity of hub networks and cognitive impairment in multiple sclerosis

Kim A. Meijer, Anand J.C. Eijlers, Linda Douw, Bernard M.J. Uitdehaag, Frederik Barkhof, Jeroen J.G. Geurts, Menno M. Schoonheim
First published May 3, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003982
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
314

Share

Article Information

vol. 88 no. 22 2107-2114
DOI: 
https://doi.org/10.1212/WNL.0000000000003982
PubMed: 
28468841
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 28, 2016
  • Accepted in final form March 6, 2017
  • First Published May 3, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Kim A. Meijer, MSc,
    2. Anand J.C. Eijlers, MD,
    3. Linda Douw, PhD,
    4. Bernard M.J. Uitdehaag, MD,
    5. Frederik Barkhof, MD,
    6. Jeroen J.G. Geurts, PhD and
    7. Menno M. Schoonheim, PhD
  1. Kim A. Meijer, MSc,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Sientific grant from Biogen Idec

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anand J.C. Eijlers, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dutch MS Research Foundation, grant number: 14-358e

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Linda Douw, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Dutch Organization for Scientific Reseach (Veni #016.146.086), (2) Society in Science - Branco Weiss Fellowship

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Bernard M.J. Uitdehaag, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis, Merck Serono, Biogen Idec, TEVA, Sanofi Genzyme and Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Frederik Barkhof, MD,
    6. Scientific Advisory Boards:

    1. Scientific consultant to Bayer-Schering, Sanofi- Aventis, Synthon, Novartis, Biogen-IDEC, Merck-Serono, Toshiba Medical systems, Roche, Janssen, TEVA, Genzyme, Eisai

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board member for Brain, Multiple Sclerosis Journal, Neuroradiology, Radiology, Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant for Synthon, Janssen, Novartis, Biogen-Idec, Roche, TEVA

    Speakers' Bureaus:

    1. Genzyme symposium speaker 2015 Novartis symposium speaker 2014 Biogen-sponsored symposium speaker 2014

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. EuroPOND co-PI (H2020), AMYPAD coordinator (IMI)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dutch foundation for MS Research - centre grant 2015-2018

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Jeroen J.G. Geurts, PhD and
    7. Scientific Advisory Boards:

    1. Scientific Advisory Board of Progressive MS Alliance, Dutch MS Research Foundation, International MS Cognition Society, Advisory Board for Genzyme and Novartis.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editor of MS Journal and BMC Neurology.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Genzyme, BIOGEN, Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dutch MS Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Menno M. Schoonheim, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Compensation for consulting services or speaker honoraria from ExceMed, Genzyme, Novartis and Biogen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dutch MS Research Foundation, grant number 13-820

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Anatomy and Neurosciences (K.A.M., A.J.C.E., L.D., J.J.G.G., M.M.S.), Neurology (B.M.J.U.), and Radiology and Nuclear Medicine (F.B.), VUmc MS Center Amsterdam, Amsterdam Neuroscience Campus, VU University Medical Center, the Netherlands; and Institutes of Neurology and Healthcare Engineering (F.B.), University College London, London, UK.
  1. Correspondence to Kim A. Meijer: k.meijer{at}vumc.nl
View Full Text

Article usage

Article usage: May 2017 to April 2023

AbstractFullPdfSource
May 20172105962Highwire
Jun 20179772132Highwire
Jul 2017232513Highwire
Aug 2017117713Highwire
Sep 20179400Highwire
Oct 20176367Highwire
Nov 20177524Highwire
Dec 20179438Highwire
Jan 20187131Highwire
Feb 20186556Highwire
Mar 20187232Highwire
Apr 20186822Highwire
May 20186277Highwire
Jun 20186955Highwire
Jul 20186184Highwire
Aug 20187643Highwire
Sep 20182611Highwire
Oct 20184433Highwire
Nov 201851106Highwire
Dec 20182901Highwire
Jan 20194336Highwire
Feb 20195643Highwire
Mar 20192213Highwire
Apr 20192575Highwire
May 20193054Highwire
Jun 201923133Highwire
Jul 201918105Highwire
Aug 201914143Highwire
Sep 20193487Highwire
Oct 20192364Highwire
Nov 20194826Highwire
Dec 20193461Highwire
Jan 20204200Highwire
Feb 20203364Highwire
Mar 20201921Highwire
Apr 20205349Highwire
May 202030104Highwire
Jun 20203513Highwire
Jul 20201123Highwire
Aug 20202784Highwire
Sep 20202121Highwire
Oct 20203120Highwire
Nov 20203942Highwire
Dec 20201510Highwire
Jan 20213051Highwire
Feb 20215102Highwire
Mar 20214831Highwire
Apr 20212012Highwire
May 20213033Highwire
Jun 20213733Highwire
Jul 20214852Highwire
Aug 20213611Highwire
Sep 20212511Highwire
Oct 20214433Highwire
Nov 20214448Highwire
Dec 20212721Highwire
Jan 20227520Highwire
Feb 20228832Highwire
Mar 20225533Highwire
Apr 20224641Highwire
May 202230191Highwire
Jun 20223753Highwire
Jul 20221302Highwire
Aug 20221232Highwire
Sep 20223222Highwire
Oct 20221711Highwire
Nov 20222733Highwire
Dec 20221651Highwire
Jan 20234121Highwire
Feb 20232421Highwire
Mar 20236692Highwire
Apr 20234010Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles